

## 2009 Upcoming Events

### Michigan Leaders Speak Life Science Program

March 11  
WMU Fetzer Center  
Kalamazoo, MI  
Philip Burton & Jay Goodwin,  
panelists, "Success Stories:  
Lessons Learned"

### AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside

March 30 – April 1  
Baltimore, MD  
Philip Burton presenting

### Apelles Partners Workshop

March 31  
Waltham, MA  
Jay Goodwin, panelist,  
"Meeting R&D Challenges  
Through Strategic Alliances"


### AAPS Northeast Regional Discussion Group "Biopharmaceutics of Oral Absorption"

April 24  
Rocky Hill, CT  
Philip Burton, keynote speaker

### AAPS Physical Pharmacy and Biopharmaceutics Section Conference: Evolving Science and Technology in Physical Pharmacy and Biopharmaceutics

May 13 – 15  
Baltimore, MD  
Philip Burton presenting

## Introducing... Our New Staff



Michelle Jump  
Associate Scientist  
Cellular Transport Studies  
mjump@admetrx.com



Marie Warren  
Client Relations  
mwarren@admetrx.com

### OUR MISSION

To improve decision-making in pharmaceutical drug discovery lead selection and lead optimization by providing high quality ADME profiling, data integration, expert analysis and predictive modeling.

### OUR VISION

To compete on quality of service rather than price or volume. We pride ourselves on treating every compound we receive, our client's intellectual property, with the care and attention that any potential therapeutic deserves. We will not allow our clients to miss such opportunities by providing imprecise, low quality data even if delivered at lower cost or quicker turnaround. We do NOT "throw the baby out with the bathwater."

### OUR VALUE PROPOSITION

Having access to experts and the skills of experienced scientists to support you, to consider and evaluate ideas, to help you predict which drug candidates are most likely to succeed...a dream for researchers. ADMETRx brings you that expertise, along with high quality ADME profiling, data integration, expert analysis and predictive modeling.

We deliver knowledge, not just data. Late stage failures are costly to the discovery and development process. Greater predictability leads to reduced time to market and lower costs of doing business, greater opportunities for success. ADMETRx adds value to your product and process by Redefining Drug Discovery. Give us a call at 269.353.5541 for a free consultation.

What clients are saying about us:

*"ADMETRx is truly unique and provides detail and insights not found anywhere else. I feel lucky to have found them."*

John W. James  
Senior Staff Scientist, Bioanalytical/DMPK  
Targacept

# ADMETRx Offers New Services!

## More Efficient Process for Selecting the First in Animal Formulation Options

Identifying early formulation options is critical to the success of your product discovery program. Our NEW standardized process will identify 2–3 optimal formulation variations for you with a small sample of compound. The new ADMETRx automated process determines solubility, evaluates potential formulation excipients, and identifies the optimal formulation choices with a maximum of three components. Confirmation of feasibility through preparation and testing of proposed formulations can be made with an additional sample.

Making the accurate early decisions about lead selection and drug candidate advancement facilitates successful drug development. ADMETRx provides high quality data integration to its discovery customers in order to provide accurate predictability and lower discovery and development costs. We also willingly share our expertise in *in vitro* drug metabolism to assist

metabolic soft spots and structure) and reactive metabolite liabilities can be assessed. All microsomal assays include appropriate controls along with test compounds. Early identification of the RIGHT metabolic structure will reduce your development costs and time to market. ADMETRx brings expert knowledge of the drug metabolism process, as well as high quality data to your early decisions in lead selection and drug candidate advancement.

WHETHER IT IS THE ABOVE TOPICS OR ANOTHER AREA OF INTEREST, we welcome the opportunity to meet with you and share our experiences. If you are interested in more information or meeting with our CSO, Dr. Philip S. Burton, to discuss your needs, we'd be glad to provide a confidentiality agreement. Please call **269.353.5541** or email [mwarren@admetrx.com](mailto:mwarren@admetrx.com) to be first to hear more about these new advances in the discovery/development process.

*“The most remarkable discovery made by scientists is science itself.”*

Gerard Piel

## Metabolite ID

Metabolism issues, such as pharmacokinetics and toxicity, can be mitigated in the early stages of development by identifying the relationship between metabolism, metabolite toxicity, and compound structure. Our newly developed Metabolite ID process provides high quality data which allows the medicinal chemist to modify the compound structure to avoid metabolic complications while maintaining the systemic absorption rate and thus accelerating the drug discovery process. Drug candidates with the most favorable characteristics can then be confidently moved forward into development in a more efficient and economical time frame.

Our new Metabolite ID process will speed up your drug discovery program with targeted predictability. The metabolism of a compound can be characterized (profile,



4717 Campus Drive  
Kalamazoo, MI 49008  
269.372.3272  
[www.admetrx.com](http://www.admetrx.com)  
[clientrelations@admetrx.com](mailto:clientrelations@admetrx.com)